22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Inhibitor of κ light polypeptide gene enhancer in B cells kinase ε (IKBKE; IKKε)

Cancer INDICATION: Melanoma; viral infection Mouse studies suggest inhibiting IKBKE could help treat melanoma and herpesvirus infections. In a mouse model of melanoma that metastasizes to the lungs, systemic IKBKE knockout decreased the number of lung...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Suppressor of IKBKE 1 (SIKE1)

Cardiovascular disease INDICATION: Heart failure Patient sample, cell culture and animal studies suggest SIKE1 could help prevent heart failure. In tissue samples from hearts of patients with dilated cardiomyopathy or hypertrophic cardiomyopathy (HCM), levels of SIKE1 mRNA...
07:00 , Mar 12, 2015 |  BC Innovations  |  Targets & Mechanisms

TBK1 and beyond

Biogen Idec Inc.'s partnership with Columbia University and the HudsonAlpha Institute for Biotechnology has yielded a new target in ALS - TBK1 - that provides a link between autophagy, neuroinflammation and the pathology of the...
08:00 , Jan 8, 2015 |  BC Innovations  |  Translation in Brief

Uptick for Lyme vaccine

Commercial interest in Lyme disease has all but ground to a halt since the withdrawal of the first vaccine, Lymerix, more than a decade ago, despite a tenfold increase in the U.S. incidence of the...
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Inhibitor of k-light polypeptide gene enhancer in B cells kinase-e (IKBKE; IKKe); Janus kinase (JAK) ...
07:00 , Mar 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer TANK-binding kinase 1 (TBK1); inhibitor of k-light polypeptide gene enhanced in B cells kinase-e (IKBKE; IKK-i);...
07:00 , Mar 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer TANK-binding kinase 1 (TBK1); inhibitor of k-light polypeptide gene enhancer in B cells kinase-e (IKBKE; IKK-i);...
08:00 , Mar 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Inhibitor of k-light polypeptide gene enhancer in B cells kinase-e...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

Domainex, Horizon Discovery Ltd. deal

Horizon and Domainex partnered to develop Domainex's TANK-binding kinase 1 (TBK1) and inhibitor of kappa light polypeptide gene enhancer in B cells kinase epsilon ( IKBKE; IKK-i) oncology research program. Horizon will...